

Form PTO-1449,

**INFORMATION DISCLOSURE EXEMPTION
IN AN APPLICATION**

(Use several sheets if necessary)

Docket Number (Optional)
GPT-024.01(22140-2401)

Application Number
09/976,283

Applicant
Dang et al.

Filing Date
October 12, 2001

Group Art Unit
~~1614~~ 1615
U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA	AA	US 4,978,332	12/18/90	Luck et al.	604	19
	AB	US 5,162,115	11/10/92	Pietronigro	424	423
	AC	US 5,213,804	05/25/93	Martin et al.	424	450
	AD	US 5,176,907	01/05/93	Leong	424	78.08
	AE	US 5,626,862	05/06/97	Brem et al.	424	426
	AF	US 5,637,085	06/10/97	Cardinale	604	49
	AG	US 5,651,986	07/29/97	Brem et al.	424	484
	AH	US 5,846,565	12/08/98	Brem et al.	424	486
	AI	US 5,886,026	03/23/99	Hunter et al.	514	449
	AJ	US 5,912,225	06/15/99	Mao et al.	514	2
	AK	US 5,952,451	09/14/99	Zhao	528	272
	AL	US 5,993,856	11/30/99	Ragavan et al.	424	489
	AM	US 6,008,318	12/28/99	Zhao et al.	528	398
	AN	US 6,153,212	11/28/00	Mao et al.	424	426
	AO	US 6,166,173	12/26/00	Mao et al.	528	398
	AP	US 6,028,163	02/22/00	Zhao	528	340
	AQ	US 6,322,797	11/27/01	Mao et al.	424	271
	AR	US 6,350,464	02/26/02	Dang	424	426
	AS	US 6,376,644	04/23/02	Mao et al.	528	398

U.S. APPLICATION DOCUMENTS

CA	AT	US20010038849	11/08/01	Dang	424	428

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
CA	AU	WO 96/03984	02/15/96	PCT W I P O			X
	AV	WO 97/40085	10/30/97	PCT W I P O			X
	AW	WO 98/42330	10/01/98	PCT W I P O			X
	AX	WO 98/44020	10/08/98	PCT W I P O			X

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**
(Use several sheets if necessary)

Docket Number (Optional)
GPT-024.01(22140-2401)

Application Number
09/976,283

Applicant
Dang et al.

Filing Date
October 12, 2001

Group Art Unit
16141615

CA	AY	WO 98/44021	10/08/98	PCT WIPO				
	AZ	WO 98/46286	10/22/98	PCT WIPO				
	BA	WO 98/48859	11/05/98	PCT WIPO				X
	BB	WO 98/58012	12/23/98	PCT WIPO				X
	BC	WO 99/65531	12/23/99	PCT WIPO				X
	BD	WO 00/19976	04/13/00	PCT WIPO				X
	BE	WO 00/41678	07/20/00	PCT WIPO				X
	BF	WO 00/64437	11/02/00	PCT WIPO				X
	BG	EP 0 057 116 A2	08/04/82	European Patent Application			English Abstract on the 1 st page	
	BH	EP 0 386 757 A2	09/12/90	European Patent Application				X
	BI	EP 0 386 757 B1	09/12/90	European Patent Specification				X

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages Etc.)

CA	BJ	Alkan-Onyuksel et al.; "A Mixed Micellar Formulation Suitable For the Parenteral Administration of Taxol", Pharmaceutical Research 11(2): 206-212, (1994)
	BK	Auerbach et al.; "Site-Specific Drug Delivery to the Lung", Polymers for Advanced Technologies 3: 323-329, (1992)
	BL	Bao et al.; "A Controlled Release Paclitaxel Formulation (PACLIMER™ delivery system) Has Superior Efficacy to Paclitaxel in an Ovarian Cancer Survival Model", Proceedings of the American Association for Cancer Research 40: Abstract #3850, (March 1999)
	BM	Burt et al.; "Controlled Delivery of Taxol from Microspheres Composed of a Blend of Ethylene-vinyl Acetate Copolymer and Poly (d, l-lactic Acid)", Cancer Letters 88: 73-79 (1995)
	BN	Chaubal et al.; "Accelerated Hydrolysis and Erosion Studies of In Vitro Degradation of Polylactofates", Proceed. Intl. Symp. Control. Rel. Bioact. Mater. 27: 656-657, (2000)
	BO	Demetrick et al.; "The Development of a Novel Intraperitoneal Tumor-Seeding Prophylactic", The American Journal of Surgery, 173: 403-406, (May 1997)
	BP	DePalma et al.; "Polyphosphoester Paclitaxel Microspheres (Paclimer™ Microspheres): In Vitro Characterization Using HPLC and LC/MS", Proceed. Intl. Symp. Control. Rel. Bioact. Mater. , 27: 532-533, (2000)
	BQ	Dhanesar et al.; " Quantitation of Insulin Released from Polyphosphoester Microspheres", Proceed. Intl. Symp. Control. Rel. Bioact. Mater. , 27: 1066-1067, (2000)
	BR	Dordunoo et al.; " Release of Taxol from Poly(ε- caprolactone) Pastes: Effect of Water-soluble additives", Journal of Controlled Released, 44: 87-94, (1997)
CA	BS	Feng et al.; " Nanospheres of Biodegradable Polymers: A System for Clinical Administration of an Anticancer Drug Paclitaxel (Taxol)", Ann. Acad. Med. Singapore 29: 633-9, (2000)

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**
(Use several sheets if necessary)

Docket Number (Optional)
GPT-024.01(22140-2401)

Application Number
09/976,283

Applicant
Dang et al.

Filing Date
October 12, 2001

Group Art Unit
1614 1615

RECEIVED
MAY 02 2002
TECH CENTER 1600 2900

BT	Francis et al.; "Phase I Feasibility and Pharmacologic Study of Weekly Intraperitoneal Paclitaxel: A Gynecologic Oncology Group Pilot Study", Journal of Clinical Oncology 13(12): 2961- 2967 (December 1995)
BU	Fu et al.; " Studies on the Melt Copolymerization of Phosphorus-containing Diacid and BIS (p- Carboxyphenoxy) Propand for DDS", j. Wuhan University(Natural Science Edition), 43(4): 467-470, (August 1997)
BV	Fu et al.; " Studies on the Syntheses and Properties of Phosphorus-Containing Polyanhydrides for DDS", Chemical Journal of Chinese University, 18: (5): 813-817, (1997)
BW	Fu et al.; " Studies on the Syntheses and Drug Release Properties of Polyanhydrides Containing Phosphonoformic (or Acetic) Acid Ethyl Ester in the Main Chain", Chemical Journal of Chinese Universities, 18(10): 1706-1710, (1997)
BX	Hagiwara et al.; " Clinical Trials With Intraperitoneal Cisplatin Microspheres for Malignant Ascites a Pilot Study", Anti-Cancer Drug Design 8: 463-470, (1993)
BY	Hagiwara et al.; " Pharmacologic Effects of Cisplatin Microspheres on Peritoneal Carcinomatosis in Rodents", Cancer 71(3): 844-850, (February 1, 1993)
BZ	Harper et al.; " Enhanced Efficacy of a Novel Controlled Release Paclitaxel Formulation (PACLIMER) Delivery System) for Local-Regional Therapy of Lung Cancer Tumor Nodules in Mice", Clinical Cancer Research 5: 4242-4248, (December 1999)
CA	Jameela et al.; " Antitumor Activity of Mitoxantrone-loaded Chitosan Microspheres Against Ehrlich Ascites Carcinoma", J. Pharm. Pharmacol. 48:685-688, (1996)
CB	Kadiyala et al.; " Poly(Phosphoesters): Synthesis, Physico-Chemical Characterization and Biological Response", Biomedical Applications of Synthetic Biodegradable Polymers, Edited by Jeffrey O. Hollinger, Chap 3, pp. 33-57, CRC Press, Inc. (1995)
CC	Kaetsu et al.; " Biodegradable Implant Composites for Local Therapy", Journal of Controlled Release 6: 249-263, (1987)
CD	Kumagai et al.; " Improvement of Intraperitoneal Chemotherapy for Rat Ovarian Cancer Using Cisplatin-containing Microspheres", Jpn. J. Cancer Res. 87: 412-417, (April 1996)
CE	Liu et al.; " Synthesis of Phosphatidyl Ethanolamine Polyphosphate Liposomal Materials", Chemical Journal of Chinese Universities, 18(9): 1556-1559, (1997)
CF	Lo, Hungnan, " Synthesis of Biodegradable Polymers and Porous Grafts for Orthopedic Applications", Thesis, Johns Hopkins University (January 27 , 1995)
CG	Mao et al., "Biodegradable Polymers: Poly(Phosphoester)s," Encyclopedia of Controlled Drug Delivery, Wiley and Sons, pp. 45-60 (1999)
CH	Mao et al., "Design of New Biodegradable Polymers Based on Chain-Extension of Oligomeric Lactides by Phosphates," Proceedings of the Topical Conference on Biomaterials Carriers for Drug Delivery and Scaffold for Tissue Engineering, Peppas, N.A. et al., eds. Los Angeles, CA, pp. 193-195 (1997)
CI	Owusu-Abadio et al.; " Efficacy of Sustained Release Ciprofloxacin Microspheres Against Device-Associated Pseudomonas Aeruginosa Biofilm Infection In a Rabbit Peritoneal Model", J. Med. Microbiol. 43: 368-376, (1995)
CJ	Pec et al.; "Biological Activity of Urease Formulated in Poloxamer 407 After Intraperitoneal Injection in the Rat", Journal of Pharmaceutical Sciences 81(7): 626-630, (July 1992)

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

(Use several sheets if necessary)

Docket Number (Optional)
GPT-024.01(22140-2401)

Application Number
09/976,283

Applicant
Dang et al.

Filing Date
October 12, 2001

Group Art Unit
1614 1615

Page 4 of 4

RECEIVED
TECH CENTER 1600
MAY 02 2017

CK	Pretula and Penczek; "High-molecular-weight Poly(alkylene phosphonate)s by Condensation of Dialkylphosphonates with Diols", Makromol. Chem. 191: 671-680, (1990)
CL	Sato et al.; "Pharmacokinetic Study of Taxol-loaded Poly(lactic-co Glicolic Acid) Microspheres Containing Isopropyl Myristate After Targeted Delivery to the Lung in Mice", Biol. Pharm. Bull. 19(12): 1596-1601, (Dec. 1996)
CM	Sharma et al.; "Antitumor Efficacy of Taxane Liposomes on a Human Ovarian Tumor Xenograft in Nude Athymic Mice", Journal of Pharmaceutical Sciences 84: (12):1400-1404, (Dec. 1995)
CN	Sharma et al.; "Novel Taxol Formulation: Polyvinylpyrrolidone Nanoparticle-Encapsulated Taxol for Drug Delivery in Cancer Therapy", Oncology Research 8 (7/8): 281-286, (1996)
CO	Suh et al.; "Regulation of Smooth Muscle Cell Proliferation Using Paclitaxel-loaded Poly(ethylene Oxide-Poly(lactide/ glycolide) Nanospheres", Journal of Biomedical Materials Research, 42(2): 331-338, (November 1998)
CP	Walter et al.; "Intratumoral Chemotherapy", Neurosurgery 37(6): 1129-1145 (Dec. 1995)
CQ	Wang et al.; "In Vitro and Vivo Evaluation of Taxol Release From Poly (lactic-cooglycolic acid) Microspheres Containing Isopropyl Myristate and Degradation of the Microspheres", Journal of Controlled Release 49: 157-166, (1997)
CR	Wang et al.; "Preparation and Characterization of Poly(lactic-co-glycolic acid) Microspheres for Targeted Delivery of a Novel Anticancer Agent Taxol", Chem. Pharm. Bull., 44(10): 1935-1940, (1996)
CS	Williams et al.; "Implantable Biodegradable Polymer for Radiosensitization of Human Glioma in Vivo", American Society for Therapeutic Radiation and Oncology (Abstract) Annual Meeting 1997
CT	Williams et al.; "Implantable Biodegradable Polymers for IudR Radiosensitization of Human Glioma in Vivo", American Society for Therapeutic Radiation and Oncology, Annual Meeting 1997.
CU	Williams et al.; "Implantable Biodegradable Polymers for IUDR Radiosensitization of Human Malignant Glioma In Vivo", American Radium Society, Abstract, Podium Presentation 1996, San Francisco.
CV	Williams et al.; "Implantable Biodegradable Polymers for IUDR Radiosensitization of Human Malignant Glioma In Vivo", American Society for Clinical Oncology Annual Meeting, Poster Presentation 1995
CW	Williams et al.; "Polymers for IUDR Radiosensitization of Experimental Glioblastoma" Congress of Neurological Surgeons Abstract: 1997
CX	Williams et al.; "Polymers for IUDR Radiosensitization of Experimental Glioblastoma" Society Neuro Oncology Abstract: Poster November 1997 Meeting
CY	Williams et al.; "Combined Intracranial IUDR polymers and 125-I Seeds for Radiosensitization of Experimental Malignant Glioma Brachytherapy", American Society for Therapeutic Radiation and Oncology Abstract Annual Meeting of 1997
CZ	Williams et al.; "Controlled Release of Radiochemicals From Implantable Biodegradable Polymer Devices", Society Nuclear Medicine Abstract: Poster MID Atlantic Meeting Submitted January 1995.
DA	Williams et al.; "Implantable Biodegradable Polymers for IUDR Radiosensitization of Experimental Human Malignant Glioma", Journal of Neuro-Oncology, 32: 181-192, (1997)

Form PTO-5449

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**
(Use several sheets if necessary)




Docket Number (Optional)
GPT-024.01(22140-2401)

Application Number
09/976,283

Applicant
Dang et al.

Filing Date
October 12, 2001

Group Art Unit
~~1614~~ 1615

	DB	Winternitz et al.; "Development of a Polymeric Surgical Paste Formulation for Taxol" Pharmaceutical Research 13(3): 368-375, (1996)
	DC	Zhang et al.; "An Investigation of the Antitumour Activity and Biodistribution of Polymeric Micellar Paclitaxel", Cancer Chemoother Pharmacol 40: 81-86, (1997)
	DD	Zhang et al.; "Biodegradable Polymeric Pastes for Taxol An In Vitro and In Vivo Study", Angiogenesis Technologies, Inc. Vancouver, BC Canada, V6E 3X1
	DE	Zhang et al.; "Development of Biodegradable Polymeric Paste Formualtions for Taxol: An in Vitro and in Vivo Study", International Journal of Pharmaceutics 137: 199- 208, (1996)
	DF	Zhao et al.; "In Vitro Degradation Studies of Polilactofates-A Copolymer of Lactide and Phosphate", Proceed. Int'l. Symp. Control. Rel.. Bioact. Mater. 27:652-653, (2000)
EXAMINER		DATE CONSIDERED 4/30/03

RECEIVED

MAY 02 2002

TECH CENTER 1600/2900

Form PTO-1449

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

(Use several sheets if necessary)

Docket Number (Optional)

GPT-024.01

Applicant

Wenbin Dang et al.

Filing Date

October 12, 2001

Application Number

09/976,286

Group Art Unit

1614 1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
CH	DG WO 02/40001	23-05-02	PCT W180				

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages Etc.)

CH	DH	Attawia et al., "Regional Drug Delivery with Radiation for the Treatment of Ewing's Sarcoma In Vitro Development of a Taxol Release System," Journal of Controlled Release 71:193-202 (2001)
	DI	Dhanesar et al., "Effect of Size on In Vitro Release of Water Insoluble Drug from Polylactofate Microspheres," Proceed. Int'l. Symp. Control. Rel. Bioact. Mater., 27(2000)
	DJ	Doiron et al., "Tumor Radiosensitization by Sustained Intratumoral Release of Bromodeoxyuridine," Cancer Research, 59:3677-3681 (1999)
	DK	Haroun et al., "Local Drug Delivery," Current Opinion in Oncology 2000, 12:187-193
	DL	Troiano et al., Sustained Release of a Model Protein from Polylactofate Microspheres," Proceed. Int'l. Symp. Control. Rel. Bioact. Mater. 27:1008-1009 (2000)
	DM	Wen et al., "New Biodegradable Polymer for Drug delivery System Poly (D,L-Lactide-CO-Ethyl Ethylene Phosphate)," Proceed. Int'l. Symp. Control. Rel. Bioact. Mater., 27(2000) Controlled Release Society, Inc.
	DN	"Update on Medicare National Coverage of Routine Costs of a Clinical Trial," Johns Hopkins Medical Research, On-Line, 7-31-02
CH	DO	International Search Report dated 14 August 2002

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE